Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Net Income towards Common Stockholders data on file, last reported at -$527.1 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 923.59% year-over-year to -$527.1 million in Q1 2026; TTM through Mar 2026 was $168.8 million, a 107.8% increase from a year earlier, with the FY2025 full-year figure at $759.9 million, up 141.2% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$527.1 million, down from $720.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for BIO reached as high as $827.8 million in Q4 2022 and fell as low as -$3.4 billion in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$345.7 million across 5 years, with a median of $64.0 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders surged 514.74% in 2024 and sank 923.59% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $827.8 million in 2022, then tumbled by 57.75% to $349.7 million in 2023, then tumbled by 304.67% to -$715.8 million in 2024, then jumped by 200.59% to $720.0 million in 2025, then slumped by 173.21% to -$527.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$527.1 million in Q1 2026, $720.0 million in Q4 2025, and -$341.9 million in Q3 2025.